⌘K
t
Scancell Holdings plc will announce its audited results for the year ended 30 April 2025 on Thursday 11 September 2025. The company will also provide a business update on progress achieved post-period end. Phillip L'Huillier, CEO, and Sath Nirmalananthan, CFO, will host a live webcast and Q&A session for analysts and investors on 11 September 2025 at 13:00 BST.
| Date | 4 Sept 2025 |
| Time | 07:00:18 |
| Category | Results |
| ID | 9201X |
4 September 2025
Scancell Holdings plc
("Scancell" or the "Company")
Notice of Final Results and Investor Presentation
Scancell Holdings plc (AIM: SCLP), the developer of Immunobody® and Moditope® active immunotherapies to treat cancer, will announce its audited results for the year ended 30 April 2025 and provide a business update on progress achieved post-period end on Thursday 11 September 2025.
Phillip L'Huillier, Chief Executive Officer, and Sath Nirmalananthan, Chief Financial Officer, will host a live webcast and Q&A session for analysts and investors on the day of the results at 13:00 BST.
If you would like to join the webcast, please follow this link:
Scancell Holdings PLC Full Year Results | SparkLive | LSEG
|
For further information, please contact: |
|
|
Scancell Holdings plc |
+44 (0) 20 3709 5700 |
|
Phillip L'Huillier, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman
|
|
|
Panmure Liberum Limited (Nominated Advisor and Joint Broker) |
+44 (0) 20 7886 2500 |
|
Emma Earl/ Will Goode, Mark Rogers (Corporate Finance) |
|
|
Rupert Dearden (Corporate Broking)
|
|
|
WG Partners LLP (Joint Broker) |
+44 (0) 20 3705 9330 |
|
David Wilson, Claes Spang
|
|
|
Investor and media relations |
|
|
Mary-Ann Chang |
+44 (0) 20 7483 284853 MaryAnnChang@scancell.co.uk
|
Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies designed to generate safe, potent and long-lasting tumour-specific immunity for a cancer-free future. The lead product, iSCIB1+, an Immunobody® active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient population that iSCIB1+, in combination with CPIs bring benefit has been identified - enabling a precision-biomarker led registrational development. The lead Moditope® peptide active immunotherapy, Modi-1, is being investigated in a Phase 2 study in a broad range of solid tumours and also has shown encouraging interim clinical data. Scancell's wholly-owned subsidiary, Glymab Therapeutics Ltd., is developing an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.